Bowman-Smart Hilary, Savulescu Julian, O'Connell Michele, Sinclair Andrew
Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, University of Melbourne, Melbourne, Australia.
J Philos Sport. 2024 Jan 2;51(1):29-53. doi: 10.1080/00948705.2024.2316294. Epub 2024 Mar 5.
World Athletics have introduced regulations preventing female athletes with certain differences in sex development from competing in the female category. We argue these regulations are not justified and should be removed. Firstly, we examine the reasoning and evidence underlying the position that these athletes have a substantial mean difference in performance from other female athletes such that it constitutes an advantage, and argue it is not sufficient. Secondly, if an advantage does exist, it needs to be demonstrated it is unfair. We argue the advantage would not be unfair because to say otherwise relies on a presupposition about whether these athletes are female, which involves contradictory and inconsistent definitions of sex. Thirdly, we contend that even if it is established that there is an advantage and it is unfair, the response of requiring athletes to take testosterone-suppressing medication is not appropriate and is unfair.
世界田径组织出台了相关规定,禁止具有特定性发育差异的女性运动员参加女子组比赛。我们认为这些规定不合理,应该予以废除。首先,我们审视了认为这些运动员与其他女性运动员在成绩上存在显著平均差异从而构成优势这一观点背后的推理和证据,并认为其并不充分。其次,如果确实存在优势,需要证明它是不公平的。我们认为这种优势并非不公平,因为否则就依赖于关于这些运动员是否为女性的先入之见,而这涉及相互矛盾且不一致的性别定义。第三,我们认为,即使确定存在优势且这种优势不公平,要求运动员服用抑制睾酮的药物这一应对措施也是不合适且不公平的。